Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 7/20 | 0.52 |
| ▸ | IDO1 | P14902 | 6/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18750633 | 0.86 | KDM4E (0.45) | PYGLIDO1KDM4EALDH1A1MAPT | |
| SCHEMBL17149909 | 0.86 | IDO1 (0.61) | PYGLIDO1ALOX15SMYD3HRH4 | |
| SCHEMBL17149847 | 0.85 | IDO1 (0.52) | PYGLIDO1ALOX15SMYD3HRH4 | |
| SCHEMBL17149615 | 0.81 | MEN1 (0.50) | PYGLIDO1ALOX15KDM4EALDH1A1 | |
| SCHEMBL17149796 | 0.80 | IDO1 (0.61) | PYGLIDO1EGFR | |
| SCHEMBL17149803 | 0.79 | MEN1 (0.51) | PYGLIDO1ALOX15KDM4EALDH1A1 | |
| SCHEMBL17149720 | 0.79 | IDO1 (0.46) | PYGLIDO1ALOX15SMYD3 | |
| SCHEMBL17149674 | 0.79 | PYGL (0.57) | PYGLALOX15KDM4EALDH1A1MAPT | |
| SCHEMBL17149621 | 0.78 | ALOX15 (0.60) | PYGLALOX15SMYD3HRH4EGFR | |
| SCHEMBL17149725 | 0.78 | ALOX15 (0.60) | PYGLALOX15SMYD3HRH4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858319-B2 | Indole derivatives for use in medicine | IOMET PHARMA LTD. (GB) | 2020-12-08 | — | — | US | disclosed |
| US-20190084933-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD. (GB) | 2019-03-21 | — | — | US | disclosed |
| US-10167257-B2 | Indole derivatives for use in medicine | IOMET PHARMA LTD. (GB) | 2019-01-01 | — | — | US | disclosed |
| US-20170107178-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD. (GB) | 2017-04-20 | — | — | US | disclosed |
| US-20170107178-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD. (GB) | 2017-04-20 | — | — | US | disclosed |
| WO-2015150097-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD (GB) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858319-B2 | Indole derivatives for use in medicine | IDO1, IDO2, TDO2 | PYGL 60/4885IDO1 1/4885ALOX15 879/4885 |
| US-10167257-B2 | Indole derivatives for use in medicine | IDO1, IDO2, TDO2 | PYGL 63/4885IDO1 1/4885ALOX15 845/4885 |
| US-20170107178-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IDO1, IDO2, TDO2 | PYGL 63/4885IDO1 1/4885ALOX15 845/4885 |
| US-20190084933-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IDO1, IDO2, TDO2 | PYGL 65/4885IDO1 1/4885ALOX15 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.